← Back to all trials
Completed
NCT05649462
Effect of Vitamin D Supplementation on Vedolizumab Response in Patients With Ulcerative Colitis
Conditions: Ulcerative Colitis, Vitamin D Deficiency, Vitamin D Supplement
Sex: All
Ages: 15 Years – 65 Years
Enrollment: 80
Sponsor: Second Affiliated Hospital of Wenzhou Medical University
Location: China
Summary
It is uncertain whether vitD3 supplementation is beneficial for the remission of ulcerative colitis (UC).
The effects of vitD3 supplements on the efficacy of vidrecizumab in Chinese UC patients were retrospectively analyzed.
Methods: Patients with moderate to severe UC were recorded.
These patients were initially treated with VDZ.
VitD3 supplementation was defined as 400IU/d vitD3 supplementation during the first infusion of VDZ and continued throughout the follow-up period.
Disease activity was assessed using the modified Mayo score.
Eligibility Criteria
Inclusion Criteria:moderate-to-severe UCTreated with VedolizumabExclusion Criteria:had recent supplementation of vitD3pregnanthad cognitive/developmental disorders that affected their ability to complete the study procedureshad medical illness or therapies potentially affecting bone, nutrition or growth statusunknown or untested baseline serum 25(OH)D level
Source: ClinicalTrials.gov (NCT05649462). StuddyBuddy aggregates publicly available trial information.
